Anti-obesity drug is entitled to additional benefits on the cardiometabolic risk factors, asked
Other positive effects on risk factors in cardiovascular expected by weight loss, no studies on the anti-obesity drug rimonabant, perhaps by the same drug, reports an article in the number June of the Drug and Therapeutics Bulletin (DTB). Ads of rimonabant (marketed as Acomplia, Sanofi-Aventis) claim that nearly 50% the impact on cardiometabolic risk factors beyond those of weight loss alone can be expected. But DTB argues that these effects were found to be due to the drug yourself.Furthermore, no published studies have compared rimonabant with other anti-obesity drugs orlistat and sibutramine. However, the effects on weight rimonobants in four clinical studies that evaluated the drug in a double-blind against placebo. The article says: In three of these reports, the
authors suggest that the effects of rimonabant on HDL cholesterol, triglycerides and HbA1c were partially independent of weight loss. However, there is no evidence that the independent effect of rimonabant in whole or in part.The article might suggest that the observed effects may be increased activity on lifestyle recommendations, related to the participants based in early studies. Is also unclear whether the effects of rimonabant on individual risk factors in a long-term reduction in risk of cardiovascular events to be translated, the article adds. . Rimonabant has not directly with other, less expensive compared to drugs for obesity. Orlistat is the drug for obesity for which there is more evidence for the efficacy and safety to date, and we have found that there are a
reasonable option for obese patients in diet and exercise and / or behavioral problems measures have not yet completed satisfactorily.Rimonabant is the most expensive for the treatment of obesity. One year treatment with rimonabant 20 mg per day costs the NHS around 720, against 520 for orlistat 120 mg three times a day and 480-570 mg of sibutramine days 10-15. Less weight and more hype with rimonabant? Drug and Therapeutics
Pages: [1] 2